Article

Understanding Legal Trends in the Life Sciences Industry

Authors

Leading Lawyers on Complying with Regulatory Changes and Keeping Abreast of Supreme Court Decisions

Jon Singer is a renowned life sciences industry leader and acclaimed trial attorney. He heads the firm’s life sciences litigation practice and has been named on of the nation’s finest life sciences trial attorneys.

In this book, “Understanding Legal Trends in the Life Sciences Industry,” his chapter discusses the current challenges and concerns with life sciences intellectual property.

From an intellectual property (IP) perspective, the legal issues in the life sciences industry are many. Probably the most important current question is what can and cannot be patented. A secondary topic of interest is what can and cannot be agreed to in settlement of the major IP cases in life sciences namely, cases under the Hatch Waxman Act between branded and generic pharmaceutical companies. The former touches every patent case in the life sciences from beginning to end; while the latter emerges from the settlement of a patent case and has consequences in antitrust, qui tam, and enforcement litigation.

His chapter is available as a complimentary PDF and can be downloaded here.

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.